MDxHealth (NASDAQ: MDXH) posts Q1 2026 growth and issues new 2026 guidance
Rhea-AI Filing Summary
MDxHealth reported Q1 2026 revenue of $27.4M, up 13% from Q1 2025, driven by its precision oncology portfolio. Gross profit rose to $16.6M, but higher operating expenses of $23.9M led to an operating loss of $7.3M and net loss of $8.9M, or $0.17 per share.
The company will discontinue its Resolve UTI business and close the Plano, Texas lab to refocus on prostate cancer diagnostics and the ExoDx acquisition. It issued new 2026 core cancer revenue guidance, excluding Resolve, of $110–115M, implying 20–26% year‑over‑year growth versus 2025 core cancer revenue.
Cash and cash equivalents were $43.2M as of March 31, 2026; on a pro‑forma basis after a $15.0M 2025 earnout payment to Exact Sciences, cash would have been $28.2M. MDxHealth also received a Medicare contractor recoupment decision of about $10.4M tied to historical Resolve claims, which it is contesting and has recorded as a contingent liability rather than a provision.
Positive
- Revenue growth and focused guidance: Q1 2026 revenue rose 13% to $27.4M, and new 2026 core cancer revenue guidance of $110–115M implies 20–26% year-over-year growth versus 2025 core cancer revenue.
Negative
- Losses, leverage and reimbursement overhang: Operating loss widened to $7.3M and adjusted EBITDA loss to $4.3M, loans and borrowings reached $95.9M, and a $10.4M Medicare recoupment decision plus upcoming restructuring charges create additional financial uncertainty.
Insights
Q1 shows solid revenue growth but rising losses, refocus, and reimbursement risk.
MDxHealth grew Q1 2026 revenue to $27.4M, up 13%, with gross profit of $16.6M. However, operating expenses increased 19% to $23.9M, expanding operating loss to $7.3M and adjusted EBITDA loss to $4.3M.
The decision to discontinue the Resolve UTI business and close the Plano lab simplifies the portfolio around prostate cancer tests and ExoDx. Management introduced 2026 core cancer revenue guidance of $110–115M, implying 20–26% growth versus 2025 core cancer revenue, but this excludes Resolve.
Liquidity is supported by $43.2M cash at quarter‑end and a net financing inflow of $16.1M, alongside higher loans and borrowings of $95.9M. A $10.4M Medicare recoupment decision on historical Resolve claims is treated as a contingent liability pending appeals, and upcoming restructuring charges from the exit plan will affect future periods.
Key Figures
Key Terms
Adjusted EBITDA financial
contingent liability financial
earnout payment financial
fair value adjustments financial
right-of-use assets financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did MDXH perform financially in Q1 2026?
What strategic changes did MDXH announce regarding the Resolve business?
What 2026 revenue guidance did MDXH provide for its core cancer business?
What is the status of MDXH’s cash position and recent payments?
What is the $10.4 million Medicare recoupment issue mentioned by MDXH?
How did MDXH’s profitability metrics and adjusted EBITDA evolve in Q1 2026?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2026
Commission File Number 001-40996
MDXHEALTH SA
(Translation of registrant’s name into English)
CAP Business Center
Zone Industrielle des Hauts-Sarts
4040 Herstal, Belgium
+32 4 257 70 21
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
MDXHEALTH SA
On May 13, 2026, MDxHealth SA (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1.
The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
| Exhibit No. | Description of Exhibit | |
| 99.1 | Press Release, dated May 13, 2026 |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| MDXHEALTH SA | |||
| Date: May 13, 2026 | By: | /s/ Michael McGarrity | |
| Name: | Michael McGarrity | ||
| Title: | Chief Executive Officer | ||
2
Exhibit 99.1
Mdxhealth Reports Q1-2026 Results
Conference call with Q&A today at 4:30 PM ET / 22:30 CET
IRVINE, California – May 13, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2026.
Michael K. McGarrity, CEO of mdxhealth, commented: “As we prioritized the integration of our recently acquired ExoDx business and to allow for renewed focus on our core prostate cancer business, we have made the strategic decision to discontinue our Resolve UTI offering and laboratory operations in Plano, Texas. The Resolve test was uniquely designed for our urology customer base to aid in the rapid diagnosis and therapy of patients presenting with often serial, complex, multi-organism infections. Despite the urgent clinical need and medical necessity of the Resolve test, the increasingly uncertain reimbursement landscape, fueled by an unexplained recent policy reversal by our Texas lab’s Medicare administrator (Novitas), has made the continued operation of this business line unsustainable. We believe this proactive exit allows us to focus our operating discipline and sales force on our prostate cancer precision diagnostics, which will drive the most value for our customers, patients and stakeholders.
We are confident that the near-term impact of this decision will augment our ability to drive sustainable growth of our prostate cancer menu, despite its associated impact on our Q1 results and 2026 guidance. We believe our renewed focus will advance market share and our ability to explore opportunities in additional urologic cancers that align with our sales force focus and customer base.
An additional benefit of this refocus has been to catalyze our commitment to leverage the promise of Artificial Intelligence (AI) into every aspect of our business. Earlier this year, we initiated an AI-dedicated strategic initiative to build-out an AI data platform throughout the company. With the hundreds of thousands of unique biopsy tissue specimens received in our laboratory, our goal is to leverage AI to improve our operating efficiency and clinical value, as well as optimize our customer experience. With our recently announced landmark PROTECT trial, the study protocol with Oxford University includes AI-enhanced endpoints, targeted to improve the performance and prognostic value of our GPS test. In addition, we have initiated a collaboration with a customer-facing digital innovation company to develop AI-enhanced offerings, building on the evidence-based clinical excellence of our tissue-based tests, thereby expanding our market opportunity in prostate and other urologic cancers.
By streamlining our operations and removing the reimbursement volatility associated with Resolve, we are effectively resetting our growth trajectory for the remainder of the year. We are establishing updated 2026 revenue guidance for our core cancer business, now excluding Resolve, of $110-115 million, which would represent 20-26% year-over-year growth over our 2025 core cancer business.”
Key highlights for the first quarter of 2026:
| ● | Revenue of $27.4 million, an increase of 13% over prior year period |
| ● | Pro-forma adjusted core revenue (excluding the Resolve business) of $23.9 million, an increase of 11% over prior year period pro-forma adjusted revenue of $21.6 million. See the “unaudited pro-forma adjusted” tables at the end of this press release for a full reconciliation of our continuing operations |
| ● | Tissue-based (Confirm mdx and GPS mdx) test volume of 11,110, a decrease of 12% over prior year period |
| ● | Liquid-based (Exo mdx and Resolve mdx) test volume of 26,235, an increase of 128% over prior year period |
| ● | Quarter-end cash and cash equivalents balance of $43.2 million |
Financial review for the quarter ended March 31, 2026
| USD in thousands (except per share data) | Quarter Ended March 31 | |||||||||||
| Unaudited | 2026 | 2025 | % Change | |||||||||
| Revenue | 27,386 | 24,292 | 13 | % | ||||||||
| Cost of goods | (10,772 | ) | (8,788 | ) | 23 | % | ||||||
| Gross Profit | 16,614 | 15,504 | 7 | % | ||||||||
| Operating expenses | (23,917 | ) | (20,092 | ) | 19 | % | ||||||
| Operating loss | (7,303 | ) | (4,588 | ) | 59 | % | ||||||
| Net loss | (8,867 | ) | (9,209 | ) | (4 | )% | ||||||
| Adjusted EBITDA* | (4,339 | ) | (1,331 | ) | 226 | % | ||||||
| Basic and diluted loss per share | (0.17 | ) | (0.19 | ) | (11 | )% | ||||||
| * | A reconciliation of IFRS to non-IFRS financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Non-IFRS Disclosure" |
Revenue increased 13% to $27.4 million compared to $24.3 million for the prior year period. Tissue-based tests accounted for 66% and 85% of total first quarter 2026 and 2025 revenue, respectively.
Gross profit increased by 7% to $16.6 million compared to $15.5 million for the prior year period. Gross margins were 60.7% compared to 63.8% for the prior year period, a reduction of 3.1 percentage points, primarily attributed to our test mix.
Operating expenses increased 19% to $23.9 million compared to $20.1 million for the prior year period, primarily driven by increases in headcount and other operating expenses related to the ExoDx acquisition.
Net loss decreased by 4% to $8.9 million compared to $9.2 million for the year period, primarily as a result of the increased operating expenses related to the ExoDx acquisition, offset by lower net financial expenses.
Adjusted EBITDA was ($4.3) million, an increase of 226% compared to ($1.3) million for the same period last year, primarily due to higher operating loss.
A reconciliation of IFRS to non-IFRS financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading "Non-IFRS Disclosure."
Cash and cash equivalents as of March 31, 2026, were $43.2 million.
Subsequent Events
On April 15, 2026, mdxhealth made its 2025 earnout payment to Exact Sciences in the amount of $15.0 million. After taking into account this earnout payment, our pro-forma cash balance as of March 31, 2026, would have been $28.2 million.
On April 20, 2026, the Company received a Medicare contractor recoupment decision from Novitas Solutions totaling approximately $10.4 million related to a retrospective review of certain historical Resolve mdx claims. The Company strongly disagrees with the contractor's findings and is vigorously contesting the contractor’s decision on substantive and procedural grounds.
Management has evaluated the matter and concluded that the recognition criteria for an accrual have not been met. The existence and ultimate amount of any obligation are contingent on the outcomes of a multi-level appeals process, which are uncertain future events not wholly within the Company's control. At this time no reliable estimate of any obligation can be made. Accordingly, the matter is accounted for as a contingent liability, and no provision has been recorded for the first quarter ended March 31, 2026.
On May 8, 2026, the Company approved a strategic plan to exit the Resolve mdx business, including the cessation of operations at its laboratory facility in Plano, Texas. As a result of this decision, the Company expects to incur restructuring and other exit-related charges in connection with the wind-down. These charges are expected to consist principally of (i) employee severance and other termination benefits, (ii) charges associated with the Plano facility lease, including accelerated amortization of the right-of-use asset and leasehold improvements, (iii) impairment of long-lived assets associated with the Resolve mdx business, including capitalized assets and equipment, (iv) charges relating to the disposition or termination of vendor and supplier contracts, and (v) other exit-related costs. The amount and timing of these charges has not been finalized and will be determined and recognized in accordance with applicable IFRS in future periods as the wind-down is executed and additional information becomes available.
2
Conference Call
Michael K. McGarrity, Chief Executive Officer and Ron Kalfus, interim Chief Financial Officer, will host a conference call and Q&A session today at 4:30 PM EST / 22:30 CET. The call will be conducted in English and a replay will be available for 30 days.
To participate in the conference call, please select your phone number below:
United States: 1-800-245-3047
Int’l: 1-203-518-9765
Belgium: 0800 72 519
United Kingdom: 0808 101 1183
Conference ID: MDX1Q26
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1758088&tp_key=21da6e9d38
To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled start time.
About mdxhealth
Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests, based on proprietary genomic, epigenomic, exosomal and other molecular technologies, assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
Non-IFRS disclosure
In addition to the Company’s financial results determined in accordance with IFRS, the Company provides adjusted EBITDA and adjusted EBITDA margin, non-IFRS measures that the Company determines to be useful in evaluating its operating performance. The Company defines adjusted EBITDA as net loss less interest expense, depreciation and amortization of intangible assets, impairment, share-based compensation, fair-value adjustments, debt extinguishment costs, provision for inventory obsolescence, reduction in force severance costs, ExoDx acquisition expenses, amendments related to the Exact Sciences earnout, income tax benefit (expense), and other financial and non-cash expenses. The Company also presents adjusted revenue, adjusted cost of goods, adjusted gross profit, adjusted operating expenses, adjusted operating loss, adjusted net loss, and adjusted basic and diluted loss per share, which exclude the impact of the recently discontinued Resolve business. Management believes that presentation of non-IFRS financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Adjusted EBITDA margin is calculated as adjusted EBITDA divided by total revenue. The Company uses this non-IFRS financial information to establish budgets, manage the Company’s business, and set incentive and compensation arrangements. However, non-IFRS financial information is presented for supplemental information purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with IFRS. For example, non-IFRS adjusted EBITDA excludes a number of expense items that are included in net loss. As a result, positive adjusted EBITDA may be achieved while a significant net loss persists. The Company’s presentation of expected non-IFRS adjusted EBITDA is a forward-looking statement about the Company’s future financial performance. This non-IFRS measure includes adjustments like share-based compensation, debt extinguishment costs, fair-value adjustments related to contingent considerations that are difficult to predict for future periods because the nature of the adjustments pertain to events that have not yet occurred. Additionally, management does not forecast many of the excluded items for internal use. Information reconciling forward-looking non-IFRS measures to IFRS measures is therefore not available without unreasonable effort and is not provided. The occurrence, timing, and amount of any of the items excluded from IFRS to calculate non-IFRS could significantly impact the Company’s IFRS results.
3
Forward-Looking Statement: This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “potential,” “expect,” “will,” “goal,” “next,” “potential,” “aim,” “explore,” “forward,” “future,” and “believes” as well as similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding expected future operating results; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated timing and benefits of our acquisitions, including estimated synergies and other financial impacts. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, product development efforts, our strategies, positioning, resources, capabilities, the anticipated results of recoupment decisions and related appeals and expectations for future events or performance. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products; the acceptance of our products and services by healthcare providers; our ability to achieve and maintain adequate levels of coverage or reimbursement for our current and future solutions we commercialize or may seek to commercialize; the willingness of health insurance companies and other payers to cover our products and services and adequately reimburse us for such products and services; changes in payer claims reimbursement practices and MDxHealth estimates regarding collection amounts for tests; the results of recoupment decisions and related appeals ;our ability to obtain and maintain regulatory approvals and comply with applicable regulations; timing, progress and results of our research and development programs; the period over which we estimate our existing cash will be sufficient to fund our future operating expenses and capital expenditure requirements; our ability to remain in compliance with financial covenants made to and make scheduled payments to our creditors; the possibility that the anticipated benefits from our business acquisitions like our acquisition of the ExoDx and GPS prostate cancer businesses will not be realized in full or at all or may take longer to realize than expected; and the amount and nature of competition for our products and services. Other important risks and uncertainties are described in the Risk Factors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS mdx, Exosome Diagnostics, ExosomeDx, Exo mdx, ExoDx, ExoDx Prostate Intelliscore (EPI), and Monitor mdx are trademarks or registered trademarks of MDxHealth SA and its affiliates. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark and all other trademarks and service marks, are the property of their respective owners.
4
|
MDxHealth SA and Subsidiaries |
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS
| Three Months Ended March 31, | ||||||||
| In thousands of $ (except per share amounts) | 2026 | 2025 | ||||||
| Revenues | $ | 27,386 | $ | 24,292 | ||||
| Cost of sales (exclusive of amortization of intangible assets) | (10,772 | ) | (8,788 | ) | ||||
| Gross profit | 16,614 | 15,504 | ||||||
| Research and development expenses | (2,134 | ) | (2,499 | ) | ||||
| Selling and marketing expenses | (12,357 | ) | (9,821 | ) | ||||
| General and administrative expenses | (8,159 | ) | (5,842 | ) | ||||
| Amortization of intangible assets | (1,265 | ) | (1,322 | ) | ||||
| Other operating (expense) income, net | (2 | ) | (608 | ) | ||||
| Operating loss | (7,303 | ) | (4,588 | ) | ||||
| Financial income | 7,385 | 692 | ||||||
| Financial expenses | (8,949 | ) | (5,176 | ) | ||||
| Loss before income tax | (8,867 | ) | (9,072 | ) | ||||
| Income tax | - | (137 | ) | |||||
| Loss for the period | $ | (8,867 | ) | $ | (9,209 | ) | ||
| Loss per share attributable to parent | ||||||||
| Basic and diluted | $ | (0.17 | ) | $ | (0.19 | ) | ||
5
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
| Thousands of $ | March 31, 2026 | December 31, 2025 | ||||||
| ASSETS | ||||||||
| Non-current assets | ||||||||
| Goodwill | $ | 39,295 | $ | 38,948 | ||||
| Intangible assets | 38,177 | 39,424 | ||||||
| Property, plant and equipment | 4,514 | 4,855 | ||||||
| Right-of-use assets | 9,303 | 9,821 | ||||||
| Financial assets | 1,649 | 1,496 | ||||||
| Total non-current assets | 92,938 | 94,544 | ||||||
| Current assets | ||||||||
| Assets held-for-sale | - | 940 | ||||||
| Inventories | 7,369 | 6,741 | ||||||
| Trade receivables | 14,261 | 14,675 | ||||||
| Prepaid expenses and other current assets | 3,110 | 2,021 | ||||||
| Cash and cash equivalents | 43,153 | 29,032 | ||||||
| Total current assets | 67,893 | 53,409 | ||||||
| TOTAL ASSETS | $ | 160,831 | $ | 147,953 | ||||
| EQUITY | ||||||||
| Share capital | $ | 219,209 | $ | 219,209 | ||||
| Issuance premium | 153,177 | 153,177 | ||||||
| Accumulated deficit | (411,901 | ) | (403,034 | ) | ||||
| Share-based compensation | 19,897 | 19,335 | ||||||
| Translation reserve | (611 | ) | (781 | ) | ||||
| Total equity | (20,229 | ) | (12,094 | ) | ||||
| LIABILITIES | ||||||||
| Non-current liabilities | ||||||||
| Loans and borrowings | 95,948 | 76,197 | ||||||
| Lease liabilities | 8,189 | 8,509 | ||||||
| Other non-current financial liabilities | 35,346 | 25,807 | ||||||
| Total non-current liabilities | 139,483 | 110,513 | ||||||
| Current liabilities | ||||||||
| Loans and borrowings | - | - | ||||||
| Lease liabilities | 1,746 | 1,898 | ||||||
| Trade payables | 12,071 | 10,330 | ||||||
| Other current liabilities | 8,478 | 6,741 | ||||||
| Other current financial liabilities | 19,282 | 30,565 | ||||||
| Total current liabilities | 41,577 | 49,534 | ||||||
| Total liabilities | 181,060 | 160,047 | ||||||
| TOTAL EQUITY AND LIABILITIES | $ | 160,831 | $ | 147,953 | ||||
6
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
| Three Months Ended March 31, | ||||||||
| Thousands of $ | 2026 | 2025 | ||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Operating loss | $ | (7,303 | ) | $ | (4,588 | ) | ||
| Depreciation | 1,125 | 925 | ||||||
| Amortization of intangible assets | 1,265 | 1,322 | ||||||
| Share-based compensation | 562 | 391 | ||||||
| Other non-cash transactions | 12 | 619 | ||||||
| Cash used in operations before working capital changes | (4,339 | ) | (1,331 | ) | ||||
| Increase (-) / decrease (+) in inventories | (628 | ) | 543 | |||||
| Decrease (+) / increase (-) in receivables | 325 | (1,107 | ) | |||||
| Increase (+) / decrease (-) in payables | 3,150 | (737 | ) | |||||
| Net cash outflow from operating activities | (1,492 | ) | (2,632 | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Purchase of property, plant and equipment | (362 | ) | (476 | ) | ||||
| Payment for Innovation Platform | (329 | ) | – | |||||
| Interests received | 191 | 489 | ||||||
| Net cash (outflow) / inflow from investing activities | (500 | ) | 13 | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Proceeds from loan obligation, net of fees | 19,400 | 24,250 | ||||||
| Repayment of loan obligation | - | (162 | ) | |||||
| Payment of lease liability | (695 | ) | (516 | ) | ||||
| Payment of interest | (2,450 | ) | (1,959 | ) | ||||
| Other financial expenses | (140 | ) | (127 | ) | ||||
| Net cash inflow from financing activities | 16,115 | 21,486 | ||||||
| Net increase in cash and cash equivalents | 14,123 | 18,867 | ||||||
| Cash and cash equivalents at beginning of period | 29,032 | 46,798 | ||||||
| Effect on exchange rate changes | (2 | ) | 7 | |||||
| Cash and cash equivalents at end of period | $ | 43,153 | $ | 65,672 | ||||
7
UNAUDITED RECONCILIATION OF IFRS TO NON-IFRS FINANCIAL MEASURES
Unaudited pro-forma adjusted P&L for the quarter ended March 31, 2026
| USD in thousands (except per share data) | Q1-2026 | Pro-forma | Q1-2026 | |||||||||
| Unaudited | As reported | Adjustment | As adjusted | |||||||||
| Revenue | 27,386 | (3,489 | )(a) | 23,897 | ||||||||
| Cost of goods | (10,772 | ) | 1,899 | (b) | (8,873 | ) | ||||||
| Gross Profit | 16,614 | (1,590 | ) | 15,024 | ||||||||
| Operating expenses | (23,917 | ) | 791 | (c) | (23,126 | ) | ||||||
| Operating loss | (7,303 | ) | (799 | ) | (8,102 | ) | ||||||
| Net loss | (8,867 | ) | (804 | ) | (9,671 | ) | ||||||
| Basic and diluted loss per share | (0.17 | ) | (0.02 | ) | (0.19 | ) | ||||||
| (a) | Represents the removal of revenue generated by the Resolve mdx business in Q1-2026 |
| (b) | Represents the removal of Resolve mdx cost of goods sold (COGS) related to Q1-2026 |
| (c) | Represents the removal of operating expenses in Q1-2026 that are directly attributable to the Resolve mdx business and will be entirely eliminated upon its closure; this excludes any allocated corporate overhead |
Unaudited pro-forma adjusted P&L for the quarter ended March 31, 2025
| USD in thousands (except per share data) | Q1-2025 | Pro-forma | Q1-2025 | |||||||||
| Unaudited | As reported | Adjustment | As adjusted | |||||||||
| Revenue | 24,292 | (2,729 | )(a) | 21,563 | ||||||||
| Cost of goods | (8,788 | ) | 1,892 | (b) | (6,896 | ) | ||||||
| Gross Profit | 15,504 | (837 | ) | 14,667 | ||||||||
| Operating expenses | (20,092 | ) | 781 | (c) | (19,311 | ) | ||||||
| Operating loss | (4,588 | ) | (56 | ) | (4,644 | ) | ||||||
| Net loss | (9,209 | ) | (50 | ) | (9,259 | ) | ||||||
| Basic and diluted loss per share | (0.19 | ) | - | (0.19 | ) | |||||||
| (a) | Represents the removal of revenue generated by the Resolve mdx business in Q1-2025 |
| (b) | Represents the removal of Resolve mdx cost of goods sold (COGS) related to Q1-2025 |
| (c) | Represents the removal of operating expenses in Q1-2025 that are directly attributable to the Resolve mdx business and will be entirely eliminated upon its closure; this excludes any allocated corporate overhead |
Unaudited pro-forma adjusted P&L Q1-2026 vs Q1-2025
| USD in thousands (except per share data) | Q1-2026 | Q1-2025 | ||||||||||
| Unaudited | As adjusted | As adjusted | % Change | |||||||||
| Revenue | 23,897 | 21,563 | 11 | % | ||||||||
| Cost of goods | (8,873 | ) | (6,896 | ) | 29 | % | ||||||
| Gross Profit | 15,024 | 14,667 | 2 | % | ||||||||
| Operating expenses | (23,126 | ) | (19,311 | ) | 20 | % | ||||||
| Operating loss | (8,102 | ) | (4,644 | ) | 74 | % | ||||||
| Net loss | (9,671 | ) | (9,259 | ) | 4 | % | ||||||
| Basic and diluted loss per share | (0.19 | ) | (0.19 | ) | - | |||||||
8
UNAUDITED RECONCILIATION OF IFRS TO NON-IFRS FINANCIAL MEASURES
| Three Months Ended March 31, | ||||||||
| In thousands of $ (except per share amounts) | 2026 | 2025 | ||||||
| IFRS net loss | $ | (8,867 | ) | $ | (9,209 | ) | ||
| Amortization of intangible assets | 1,265 | 1,322 | ||||||
| Depreciation expense | 1,125 | 925 | ||||||
| Share-based compensation expense | 562 | 391 | ||||||
| Interest expense, net | 2,845 | 1,859 | ||||||
| Income tax expense | - | 137 | ||||||
| Fair value adjustments (1) | (1,397 | ) | 2,547 | |||||
| Other adjustments (2) | 128 | 697 | ||||||
| Adjusted EBITDA | $ | (4,339 | ) | $ | (1,331 | ) | ||
| 1) | Primarily related to GPS and ExoDx contingent considerations, GPS earnout amendment, Exact Sciences 5-year warrants, and option to pay Exact Sciences and Bio-Techne earnout in shares |
| 2) | Bank fees and other non-cash expenses |
For more information:
info@mdxhealth.com
LifeSci Advisors (IR & PR)
John Fraunces, Managing Director
Tel: +1 917 355 2395
jfraunces@lifesciadvisors.com
9